The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
The Japanese drugmaker agreed to acquire Texas-based IntraBio in a deal valued at $2 billion by reporting outlets, absorbing an asset that generated $68 million in 2025 sales according to Shionogi.
ViiV Healthcare said its long-acting injectable combination of cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor, achieved superior viral suppression rates at six months compared to standard daily oral therapy.
Adding Epkinly, a bispecific antibody targeting CD3 and CD20, to standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% in patients with newly diagnosed diffuse large B-cell lymphoma.
Lycia Therapeutics has filed to go public on the Nasdaq to advance its pipeline of lysosome-targeting chimeras, or LYTACs, which degrade extracellular and membrane-bound proteins.
The FDA issued a request for information to guide the design of early-phase clinical trials for ibogaine drug candidates, seeking input on dosing, safety monitoring, care settings, and stopping rules.
Roche's Genentech unit will pay Alector $100 million upfront, alongside up to $1.17 billion in potential milestones that bring the deal's total value to $1.27 billion, for exclusive global rights to AL050.
The expanded multi-year agreement adds one target, with an option for a second, to discover small molecules that stop the secretion of disease-driving proteins using Gate's Molecular Gate drug discovery engine.
CSL will pay Alentis Therapeutics $355 million upfront and up to $1.2 billion in milestones to co-develop and co-commercialize lixudebart, a monoclonal antibody targeting Claudin-1.
In the Opus-1 Phase 3 trial in adults, the company's 31-valent pneumococcal conjugate vaccine, VAX-31, met non-inferiority criteria against all 20 bacterial strains in Pfizer's Prevnar 20 and 17 of 19 strains in Merck's Capvaxive.
Updated clinical data for EPI-321 showed a 3% increase in muscle volume at six months in patients with facioscapulohumeral muscular dystrophy, or FSHD.
The Nobel Assembly at Karolinska Institutet awarded the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann, and Georg Nagel for developing optogenetics.
In Part C of the Phase 1/2 Rainfol-01 trial of 109 patients with platinum-resistant ovarian cancer, Genmab reported a median progression-free survival of 9.5 months for its folate-receptor-alpha-targeting antibody-drug conjugate rinatabart sesutecan.
Researchers built a deep-learning framework that embeds directed causal graphs mined from toxicology literature directly into predictive models, mapping chemical structures to multi-target perturbation profiles.
Researchers developed HALO, a machine-learning framework trained on 3,160 drug-pair-strain interactions across 97 antibacterial compounds and 10 bacterial strains to predict whether pairs of antibiotics work better together.
Researchers introduced AlphaProtein Novo, a machine-learning pipeline that builds functional enzymes from scratch without starting from natural protein backbones.
Researchers combined molecular simulations and machine learning across four screening rounds to prospect natural hydroxymethylfurfural oxidases for synthesizing the bioplastic precursor 2,5-furandicarboxylic acid (FDCA).
Training spatial transcriptomic foundation models alongside matched tissue images does not consistently improve their ability to transfer cell annotations across donors, according to benchmarks across three models.
A computational framework called scBOLT simplifies the process of turning single-cell RNA sequencing data across multiple experimental conditions into Boolean logic models of gene regulation.
Researchers introduced FD-SCoPE, an auditable language-model system designed to answer clinical questions using trial summary tables, including requests that require inferring unlisted drug targets or harmonized endpoints.
Researchers introduced scEGFlow, a framework combining conditional flow matching with energy guidance to model how individual cells shift in appearance and gene expression following biological perturbations.